Alnylam Can Survive Being ‘Punched in the Face,’ President SaysBy
Company’s value nearly halved after shuttering drug trial
Alnylam confident in safety of other products in testing
Alnylam Pharmaceuticals Inc. is ready to soldier on with other projects after the news that it’s shutting down a key therapy program cut its market value by almost half in a day.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.